SALT LAKE CITY - Recursion Pharmaceuticals (NASDAQ:RXRX) announced Monday that its investigational drug REC-4881 demonstrated significant polyp reduction in patients with familial adenomatous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results